Molecular pathogenesis of malignant lymphomas: PTCL, NOS and AITL

Malignant Lymphomas: Biology and Molecular Pathogenesis

Volumn , Issue , 2016, Pages 311-328

  Rodríguez Cortés, José ^a   Ferrando, Adolfo ^a   Palomero, Teresa ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026682573     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110366914-018     Document Type: Chapter

References (129)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW Pathology and genetics of tumours of hematopoietic and lymphoid tissues. World Health Organization classification of tumours. International Agency for Research on Cancer Press, Lyon, 2008;(11):270-299.
2. de Leval L, et al. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol, 2009;72(2):125-143.
3. Willenbrock K, et al. Analysis of T-cell subpopulations in T-cell non-Hodgkin’s lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor- beta gene rearrangements. Am J Pathol 2001;158(5):1851-1857.
4. Willenbrock K, et al. In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch 2005;446(1):15-20.
5. Attygalle AD, et al. CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2004;28(1):54-61.
6. Dupuis J, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006;30(4):490-494.
7. Dorfman DM, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006;30(7):802-810.
8. de Leval L, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (Tfh) cells. Blood 2007;109(11):4952-4963.
9. Grogg KL, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006;19(8):1101-1107.
10. Roncador G, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007;92(8):1059-1066.
11. Campo E, et al. Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol 1998;9(8):835-843.
12. Vose J, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-4130.
13. Iannitto E, et al. Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol 2008;68(3):264-271.
14. Mosalpuria K, Bociek RG, Vose JM. Angioimmunoblastic T-cell lymphomamanagement. Semin Hematol 2014;51(1):52-58.
15. Siegert W, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995;6(7):659-664.
16. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010;148(5):673-689.
17. Cho YU, et al. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol 2009;131(5):640-66.
18. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003;121(5):681-691.
19. Mourad N, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2008;111(9):4463-4470.
20. Schaerli P, et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192(11):1553-1562.
21. Kim CH, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 2001;193(12):1373-1381.
22. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192(11):1545-1552.
23. Chtanova T, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-TH1/TH2 effector cells that provide help for B cells. J Immunol 2004;173(1):68-78.
24. Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 2015;16(2):142-152.
25. Vinuesa CG, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005;435(7041):452-458.
26. Choi YS, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011;34(6):932-946.
27. King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009;9(11):757-766.
28. Vinuesa CG, et al. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005;5(11):853-865.
29. Piccaluga PP, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007;67(22):10703-10710.
30. Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol 2014;51(1):5-16.
31. Goenka R, et al. Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell programbut cannot complete ultimate effector differentiation. J Immunol 2011;187(3):1091-1095.
32. Stone EL, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity 2015;42(2):239-251.
33. Weber JP, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Kruppel-like factor 2. J Exp Med 2015;212(2):217-233.
34. Leavenworth JW, et al. A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 2015;16(1):96-106.
35. Crotty S. T follicular helper cell differentiation function, and roles in disease. Immunity 2014;41(4):529-542.
36. Liu X, Nurieva RI, Dong C. Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol Rev 2013;252(1):139-145.
37. Nurieva RI, et al. Bcl6 mediates the development of T follicular helper cells. Science 2009;325(5943):1001-1005.
38. Yu D, et al. Lineage specification and heterogeneity of T follicular helper cells. Curr Opin Immunol 2009;21(6):619-625.
39. Johnston RJ, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009;325(5943):1006-1010.
40. Qi H, et al. Tfh cell differentiation and their function in promoting B-cell responses. Adv Exp Med Biol 2014;841:153-180.
41. Hatzi K, et al. BCL6 orchestrates Tfhcell differentiation viamultiple distinct mechanisms. J Exp Med 2015;212(4):539-553.
42. Liu X, et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 2014;507(7493):513-518.
43. Kroenke MA, et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol 2012;188(8):3734-3744.
44. Kwon H, et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009;31(6):941-952.
45. Nurieva RI, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008;29(1):138-149.
46. Liao W, et al. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011;12(6):551-559.
47. Choi YS, et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol 2013;190(8):4014-4026.
48. Nurieva RI, Dong C. (IL-)12 and 21: a new kind of help in the follicles. Immunol Cell Biol 2009;87(8):577-578.
49. Suto A, et al. Development and characterization of IL-21-producing CD4+ T cells. J Exp Med 2008;205(6):1369-1379.
50. Ma CS, et al. Early commitment of naive human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol 2009;87(8):590-600.
51. Schmitt N, et al. IL-12 receptor beta1 deficiency alters in vivo T follicular helper cell response in humans. Blood 2013;121(17):3375-3385.
52. Schmitt N, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009;31(1):158-169.
53. Walker SR, et al. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol 2013;33(15):2879-2890.
54. Johnston RJ, et al. STAT5 is a potent negative regulator of Tfh cell differentiation. J Exp Med 2012;209(2):243-250.
55. Nurieva RI, et al. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem 2012;287(14):11234-11239.
56. Martinez-Delgado B, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005;19(12):2254-22563.
57. Ballester B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25(10):1560-1570.
58. Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol 2006;24(3):113-119.
59. Piccaluga PP, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007;117(3):823-834.
60. Cuadros M, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007;25(22):3321-3329.
61. Iqbal J, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010;115(5):1026-1036.
62. Iqbal J, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014;123(19):2915-2923.
63. Gaulard P, de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol 2014;24:49-60.
64. Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol 2014;99(3):219-226.
65. Zettl A, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004;164(5):1837-1848.
66. Thorns C, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer 2007;46(1):37-44.
67. Nelson M, et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 2008;141(4):461-469.
68. Streubel B, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006;20(2):313-318.
69. Rigby S, et al. The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation. J Biol Chem 2009;284(39):26871-26881.
70. Pechloff K, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 2010;207(5):1031-1044.
71. Dierks C, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 2010;70(15):6193-6204.
72. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005;21:247-269.
73. Boulter E, et al. Off the beaten paths: alternative and crosstalk regulation of Rho GTPases. FASEB J 2012;26(2):469-479.
74. del Pozo MA, et al. Rho GTPases control migration and polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes. Eur J Immunol 1999;29(11):3609-3620.
75. Heasman SJ, et al. Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol 2010;190(4):553-563.
76. Heasman SJ, Ridley AJ. Multiple roles for RhoA during T cell transendothelial migration. Small GTPases 2010;1(3):174-179.
77. Mou F, et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J Exp Med 2012;209(4):741-759.
78. Corre I, et al. Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med 2001;194(7):903-914.
79. Henning SW, et al. The GTPase Rho has a critical regulatory role in thymus development. EMBO J 1997;16(9):2397-2407.
80. Galandrini R, Henning SW, Cantrell DA. Different functions of the GTPase Rho in prothymocytes and late pre-T cells. Immunity 1997;7(1):163-174.
81. Cleverley S, Henning S, Cantrell D. Inhibition of Rho at different stages of thymocyte development gives different perspectives on Rho function. Curr Biol 1999;9(12):657-660.
82. Cleverley SC, et al. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 2000;19(1):13-20.
83. Zhang S, et al. Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development. J Immunol 2014;193(12):5973-5982.
84. Angkachatchai V, Finkel TH. ADP-ribosylation of rho by C3 ribosyltransferase inhibits IL-2 production and sustained calcium influx in activated T cells. J Immunol 1999;163(7):3819-3825.
85. Pernis AB. Rho GTPase-mediated pathways in mature CD4+ T cells. Autoimmun Rev 2009;8(3):199-203.
86. Palomero T, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014;46(2):166-170.
87. Sakata-Yanagimoto M, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46(2):171-175.
88. Yoo HY, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46(4):371-375.
89. Rohde M, et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 2014;53(11):911-916.
90. Kakiuchi M, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014;46(6):583-587.
91. Wang K, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46(6):573-582.
92. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324(5929):930-935.
93. Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion ES-cell self-renewal and inner cell mass specification. Nature 2010;466(7310):1129-1133.
94. Cimmino L, et al. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011;9(3):193-204.
95. Pronier E, Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr Hematol Malig Rep 2012;7(1):57-64.
96. Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114(1):144-147.
97. Vose JM. Update on T-cell lymphoma. Ann Oncol 2008;19 Suppl 4:iv74-6.
98. Couronne L, C Bastard, and OA Bernard, TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012;366(1):95-96.
99. Lemonnier F, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with Tfh-like features and adverse clinical parameters. Blood 2012;120(7):1466-1469.
100. Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20(1):25-38.
101. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20(1):11-24.
102. Li Z, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118(17):4509-4518.
103. Ko M, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011;108(35):14566-14571.
104. Ko M, Rao A. TET2: epigenetic safeguard for HSC. Blood 2011;118(17):4501-4503.
105. Koh KP, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011;8(2):200-213.
106. Kunimoto H, et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep 2012;2:273.
107. Shide K, et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012;26(10):2216-2223.
108. Muto H, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 2014;4:e264.
109. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363(25):2424-2433.
110. Shah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat Genet 2011;43(4):289-290.
111. Thiede C. Mutant DNMT3A: teaming up to transform. Blood 2012;119(24):5615-7.
112. Cairns RA, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012;119(8):1901-1903.
113. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010;16(9):387-397.
114. Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther 2015;152:54-62.
115. Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 2015;102(5):523-527.
116. Ahearne MJ, et al. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br J Haematol 2014;166(3):326-335.
117. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23(48):7990-8000.
118. Cotta CV, Hsi ED. Pathobiology of mature T-cell lymphomas. Clin Lymphoma Myeloma 2008;8 Suppl 5:S168-179.
119. Carbone A, et al. The role of inflammation in lymphoma. Adv Exp Med Biol 2014;816:315-333.
120. Beachy SH, et al. Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma. Blood 2012;120(5):1048-1059.
121. Viswanathan SR, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009;41(7):843-848.
122. Wang X, et al. TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest 2011;121(10):3834-3845.
123. Roberts CW, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 2004;4(2):133-142.
124. Margol AS, Judkins AR. Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet 2014;207(9):358-364.
125. Schmitz U, et al. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001;84(2):199-201.
126. Sevenet N, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotypephenotype correlations. Hum Mol Genet 1999;8(13):2359-2368.
127. Ellyard JI, et al. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphomalike tumors in mice. Blood 2012;120(4):812-821.
128. Nguyen TB, et al. Double somatic mosaic mutations in TET2 and DNMT3A-origin of peripheral T cell lymphoma in a case. Ann Hematol 2015;94(7):1221-1223.
129. Sato F, et al. Angioimmunoblastic T-cell lymphoma mice model. Leuk Res 2013;37(1):21-27.